Orange backs startup Biolevate in pharma AI push

Anne Morris2026-09-23T12:45:00

Source: Unsplash / Ecliptic Graphic

Orange Ventures co‑led a Series A funding round for the health‑tech specialist.

This article includes:

Organisations: Biolevate; Business & Decision; Business & Decision Life Sciences; Capgemini; Dataiku; Enovacom; Enovalife; EQT Ventures; French Tech 2030; Future4Care; Generali; MSD Global Health Innovation Fund; Mutuelle Nationale des Hospitaliers; NEHS Digital; Orange; Orange Business; Orange Ventures; RAISE France; Sanofi; Station F; Xperis.
Geographies: Europe; France; North America; United States of America (USA).
People: Aymar Hénin; Claire Scotton; Jérôme Berger.
Themes: Agentic AI; AI agents; AI automation; AI integration; Artificial intelligence; Auditable workflows; Biotechnology; Clinical research; Clinical trials; Contract research organisation; Data management; Digital healthcare; Digital solutions; Drug lifecycle; Drug development; Enterprise-grade platform; Evidence-grade workflows; Frontier AI; Health technology; Healthcare; Human oversight; Knowledge-driven automation; Life sciences; Medical research; Operational costs; Pharmaceutical industry; Pharmaceutical research and development; Regulatory compliance; Regulatory knowledge; Responsible AI; Security; Time-to-market; Traceability; Trusted AI; Venture capital.

Register for free to continue reading this article

Already registered? Sign in here.

By registering for a free account, you will get immediate access to the rest of this article, plus:

“The detail is very good. Better than we get internally.” – GM, Vodafone OpCo

Want full access to TelcoTitans content? Check out our subscription options.